Pyxis Oncology, Inc. Tax Withholding Paid on Stock Awards
Pyxis Oncology, Inc. (PYXS) reported Tax Withholding Paid on Stock Awards of $78.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-13
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $53.00K, a 20.90% decline year-over-year.
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $25.00K, a 1150.00% increase year-over-year.
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $71.00K.
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $8.00K, a 700.00% increase year-over-year.
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $148.00K, a 38.33% decline from fiscal 2024.
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $240.00K, a 46.07% decline from fiscal 2023.
- Pyxis Oncology, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $445.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $78.00K 10-Q · filed 2026-08-13 | $149.00K derived: sum of 3 quarters · filed 2026-08-13 | $157.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $25.00K 10-Q · filed 2026-05-14 | $96.00K derived: sum of 2 quarters · filed 2026-05-14 | $104.00K derived: sum of 3 quarters · filed 2026-05-14 | $171.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $79.00K derived: sum of 2 quarters · filed 2026-03-23 | $146.00K derived: sum of 3 quarters · filed 2026-08-13 | $148.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $75.00K derived: sum of 2 quarters · filed 2026-08-13 | $77.00K 10-Q · filed 2025-11-03 | $77.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $69.00K 10-Q · filed 2026-08-13 | $69.00K derived: sum of 3 quarters · filed 2026-08-13 | $70.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-14 | $2.00K derived: sum of 2 quarters · filed 2026-05-14 | $3.00K derived: sum of 3 quarters · filed 2026-05-14 | $46.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.00K derived: sum of 2 quarters · filed 2026-03-23 | $44.00K derived: sum of 3 quarters · filed 2026-03-23 | $240.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $44.00K derived: sum of 2 quarters · filed 2025-11-03 | $240.00K 10-Q · filed 2025-11-03 | $292.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $239.00K 10-Q · filed 2025-08-14 | $291.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $196.00K 10-Q · filed 2025-05-15 | $248.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $445.00K 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $393.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |